Readers of our pipeline page will notice that several programs list an ‘undisclosed’ molecular target. That’s a deliberate, temporary choice tied to patent strategy — publishing a specific target before filing can create prior-art complications — not an attempt to obscure the science.
What we do disclose is the mechanism class, the modality, and the stage, because those are the things a patient advocacy group, an investor, or a fellow researcher actually needs to evaluate the program honestly.